|View printer-friendly version|
|October 12, 2006 1:59 p.m.|
|Teva Announces Tentative Approval for Generic Risperdal® Oral Solution|
Jerusalem, Israel, October 12, 2006 - Teva Pharmaceutical Industries Ltd. (Nasdaq: TEVA) announced today that the U.S. Food and Drug Administration has granted tentative approval for the Company's Abbreviated New Drug Application (ANDA) to market its generic version of Janssen's Risperdal® (Risperidone) Oral Solution, 1 mg/mL. Final approval is expected upon expiry of patent protection for the brand product on December 29, 2007.